====== Regorafenib ======

===== Latest Pubmed Related Articles =====


{{rss>https://pubmed.ncbi.nlm.nih.gov/rss/search/1JUQiFFHYgOpKyzQPPcZ0CmbM1kinq8Usiy_EB_WHRBUMF0wDF/?limit=15&utm_campaign=pubmed-2&fc=20230324081621}}
----
Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal, and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual-targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types.

By 2015 it had 2 US approvals for advanced cancers. 

[[Antiangiogenic]] treatment approaches have failed to improve outcomes in randomized trials of [[high-grade astrocytoma]]. One key mechanism of resistance to antiangiogenic treatment may concern the upregulation of alternative pro-angiogenic pathways. Regorafenib is a potent multikinase inhibitor that may alter some of those pathways
((Tzaridis T, Gepfner-Tuma I, Hirsch S, Skardelly M, Bender B, Paulsen F, Schaub
C, Weller J, Schäfer N, Herrlinger U, Tabatabai G. Regorafenib in advanced
high-grade glioma: a retrospective bicentric analysis. Neuro Oncol. 2019 Apr 23. 
pii: noz071. doi: 10.1093/neuonc/noz071. [Epub ahead of print] PubMed PMID:
31089718.
)).


====== Side effects ======

[[Regorafenib side effects]]

====== Regorafenib for glioblastoma ======
[[Regorafenib for glioblastoma]].